News | August 08, 2024
Balaji Amines Q4 FY25 revenue stood at Rs. 393 Cr
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
Expect the international business including CDMO business to pick-up in the second half of the financial year
Organization to provide vaccinations & treatments for several monsoon related diseases and illnesses across all 102 clinics
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
